The major press was all over a study that came out a couple weeks ago observing carbon nanotubes and C60 buckyballs (or fullerenes) to have potential carcinogenic pathologies.
The following originally appeared in the complementary e-zine Nanotech Investing News.
Good news keeps rolling in for the developer of VivaGel. From an investor standpoint, the best news is the announcement that the deputy chairman and nonexecutive director picked up a sizeable chunk of shares recently, some at the American Depositary Receipt (ADR) equivalent of $3.55 a share.
My biggest issue with the whole Green Tech trend is that most people are looking for that one big solution and betting all their money on a horse that not only isn’t in the race but isn’t even born yet.
General Atomics’ Predator made unmanned aerial vehicles (UAV) famous after it took out a Jeep-load of al Qaeda leaders traveling through the Yemeni desert.
Alimera Sciences announced today that a new trial that has commenced with pSivida’s Medidur for age-related macular edema (AMD). Per the revised agreement with Alimera, Alimera is funding the trial, and pSivida will get 20 percent of any profits down the line.
It’s likely that, if you follow the nightly news, read the paper or even scan your customized Google News browser, you missed one of the biggest scientific discoveries to come around in a long time. No, it wasn’t that Britney got the kids back.
Certainly, it’s important to keep up with the earnings on the Big Dogs, but it’s always more fun to check in on what’s happening when the Pioneers report.
The following originally appeared in my complementary e-zine, Nanotech Investing News.
Solar power is becoming the latest niche frenzy in the Green Tech and nanotech space. There’s all sorts of talk about thin film solar and printable photovoltaic (PV) cells using nanorods or nanotubes.
